Related Experiment Video

Updated: Jul 4, 2025

Characterizing RNA Modifications in Single Neurons Using Mass Spectrometry
08:45

Characterizing RNA Modifications in Single Neurons Using Mass Spectrometry

Published on: April 21, 2022

2.4K

The RNA m6A writer METTL3 in tumor microenvironment: emerging roles and therapeutic implications

Weiqi Su1, Lin Che1, Wenting Liao1

  • 1State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

Frontiers in Immunology
|February 7, 2024
PubMed

Insights

Methyltransferase-like 3 (METTL3) influences the tumor microenvironment (TME) and anti-cancer immunity. This review details METTL3

Area of Science:

  • Oncology
  • Immunology
  • Epigenetics

Background:

  • The tumor microenvironment (TME) is crucial for tumor progression and immunotherapy response.
  • Methyltransferase-like 3 (METTL3) regulates the m6A epitranscriptome and impacts cancer cells.
  • METTL3's role in the TME and anti-cancer immunity requires comprehensive summarization.

Purpose of the Study:

  • To systematically review METTL3 functions within the TME.
  • To elucidate METTL3's effects on tumor-infiltrating immune cells.
  • To explore m6A-dependent mechanisms and therapeutic targeting strategies.

Main Methods:

  • Literature review and synthesis of existing research on METTL3.
  • Analysis of METTL3's impact on immune cell populations within the TME.
  • Examination of m6A modification pathways and their relation to METTL3.

Main Results:

  • METTL3 significantly influences various immune cell types within the TME.
  • Dysregulation of METTL3 impacts anti-cancer immunity.
  • m6A modifications mediated by METTL3 are key to its TME functions.

Conclusions:

  • METTL3 plays a critical role in shaping the TME and modulating anti-cancer immunity.
  • Targeting METTL3 presents a promising strategy to enhance immunotherapy efficacy.
  • Further research into METTL3-m6A interactions is warranted for novel therapeutic development.
Keywords:
N6-methyladenosine (m6A)cancer immunotherapyimmune checkpoint inhibitors (ICI)methyltransferase-like 3 (METTL3)small molecular inhibitorstumor-infiltrating immune cells (TICs)

More Related Videos

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues08:56

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues

Published on: December 5, 2016

10.9K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.3K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
RNA Stability01:53

RNA Stability

Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
33.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K